+113%

est. 2Y upside i

HealthcareSeries A

Medical coding automation

Rank

#404

Sector

Healthcare IT

Est. Liquidity

~5Y

Data Quality

Data: Low

Arintra is a high-conviction, high-risk equity opportunity anchored by ~700% YoY revenue growth (from ~$2M to $16.2M ARR) backed by Peak XV Partners.

Last updated: May 13, 2026

Bull (32%)+320%

Arintra sustains 100%+ annual growth, reaching ~$65M ARR by mid-2028, and closes a Series B at 10x ARR (~$650M valuation), delivering ~320% upside before dilution. Peak XV's brand and deep Epic/Athena integrations catalyze a large health-system land-and-expand flywheel that crowds out RapidClaims and Access Healthcare.

Base (43%)+65%

Growth decelerates to ~50% YoY as enterprise sales cycles lengthen; $36M ARR by 2028 supports a Series B at ~$220M (~6x ARR), yielding ~65% mark-to-market upside after ~20% dilution from new preferred issuance. Arintra remains a credible independent platform but faces pricing pressure from better-capitalized competitors.

Bear (25%)-70%

Growth stalls below 20% as Epic and Athena Health deepen native coding features; a down round or acqui-hire at $40–60M triggers $21.5M in senior liquidation preferences, leaving common stockholders with less than 30 cents on the dollar. Customer concentration in community-tier health systems amplifies churn risk.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Funding Intensity

1790%

$21.5M total funding against an estimated ~$120M post-money Series A valuation implies ~18% of exit proceeds are senior to common equity — any exit below ~$80M returns nothing to common stockholders.

Dilution Risk

high

A Series A company at this growth rate will require at least 2 more institutional rounds (Series B and C) before exit, each adding 15–25% dilution and deepening the preference stack ahead of common equity.

Secondary Liquidity

none

No secondary market evidence exists for a 124-person Series A healthtech company; meaningful liquidity is contingent on a primary exit event realistically 5+ years out.

Other — 1 role

View all 1 open roles at Arintra →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Arintra's data — designed to show you've done your homework.

  • 1

    “Your February 2026 press release cites 8X revenue growth to $16.2M ARR — can you break down growth between new logo acquisition versus expansion ARR within existing customers, and what is the current net revenue retention rate?”

  • 2

    “What percentage of ARR comes from direct health system subscriptions versus API licensing to other healthtech companies, and what does average contract value and sales cycle look like when targeting enterprise IDNs versus the community hospitals in your current customer list?”

  • 3

    “What was the post-money valuation at the August 2025 Series A close, is the liquidation preference participating or non-participating, and does the company have a plan for employee secondary liquidity or tender offers prior to a primary exit event?”

Community

Valuation Sentiment

Our model estimates +113% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.